Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection

Article Abstract:

One of the experimental treatments for cancer which may prove effective is the attachment of radioisotopes to specific antibodies. If the antibodies preferentially bind to cancer cells, this method provides a way to deliver the radiation dose more precisely to the tumor and to spare more of the normal tissue. Experiments in mice have demonstrated the effectiveness of antibodies against the molecule isoferritin labelled with iodine-131 in the treatment of transplanted human hepatocellular carcinoma, a liver cancer. To investigate the potential clinical benefits of this method, 25 patients with hepatocellular carcinoma that was not surgically treatable were treated with radiolabeled antibodies. Thirty-seven patients who did not receive this treatment were available as controls. Although a greater number of patients from the group treated with the radioactive antibodies survived two years after treatment, the results were not statistically significant, and further studies involving a larger number of patients will be necessary. (Consumer Summary produced by Reliance Medical Information, Inc.)

Care and treatment, Liver cancer, Radioimmunotherapy

---

Stopping cancer before it colonizes

Article Abstract:

Scientists have earlier reported that the cell membrane protein KA11 binds the Duffy blood group glycoprotein, a protein expressed on the vascular endothelium, the binding of which inhibits cancer cell proliferation at distant sites and ultimately induces expression of markets of cellular senescence. A study provides initial data to identify the critical binding regions necessary for the association of KA11 is presented.

HEALTH SERVICES, Cancer Therapy, Ambulatory Health Care Services, Cancer treatment

---

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

Article Abstract:

Research shows osteopontin is the lead gene in the causation of hepatocellular carcinoma and metastasis and it is over-expressed in metastatic hepatocellular carcinoma as determined by the hepatocellular carcinoma-specific antibody blocking the cancer invasion in vitro.

China, Analysis, Cancer research, Physiological aspects, Genetic aspects, Gene expression, Antigen-antibody reactions, Hepatoma, Hepatocellular carcinoma

Similar abstracts:

• Abstracts: Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. Long-term Weight Loss With Sibutramine: A Randomized Controlled Trial
• Abstracts: Composite outcomes in randomized trials: greater precision but with greater uncertainty? Clinical trials -- multiple treatments, multiple end points, and multiple lessons
• Abstracts: Managing behavioral health in Medicaid. The pharmaceutical industry versus medicaid-limits on state initiatives to control prescription-drug costs

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.